Press Releases

Press Releases

    Date Title View
    07/01/20
    Summary ToggleNew Initiative Encourages the Graves’ Disease Community to FOCUS on Eye Health
    PDF Version
    06/03/20
    Summary ToggleHorizon Therapeutics plc Announces Redemption of All $400 Million of Its Exchangeable Senior Notes
    PDF Version
    06/03/20
    Summary ToggleData Presented on KRYSTEXXA® (pegloticase injection) Co-Prescribed with an Immunomodulator Adds to Growing Body of Evidence for this Treatment Approach
    PDF Version
    05/21/20
    Summary ToggleHorizon Therapeutics Named Number One Best Workplace in Chicago
    PDF Version
    05/21/20
    Summary ToggleData on Multiple Immunomodulation Approaches with KRYSTEXXA® (pegloticase injection) to be Presented at the Annual European Congress of Rheumatology (EULAR 2020)
    PDF Version
    05/19/20
    Summary ToggleHorizon Therapeutics to Participate in Upcoming Investor Conferences
    PDF Version
    05/14/20
    Summary ToggleNew Data on the Pharmacokinetic Profile of TEPEZZA™ (teprotumumab-trbw) Reinforce the Labeled Dosing Regimen, Indicating a Positive, Consistent Response to Therapy
    PDF Version
    05/11/20
    Summary ToggleU.S. Physician Survey Illustrates the Devastating Impact of Thyroid Eye Disease on Patient Quality of Life
    PDF Version
    05/06/20
    Summary ToggleHorizon Therapeutics plc Reports Strong First-Quarter 2020 Financial Results; Increasing TEPEZZA™ Full-Year 2020 Net Sales Guidance to Greater Than $200 Million Due to Rapid Uptake; Increasing Full-Year 2020 Net Sales Guidance
    04/27/20
    Summary ToggleHorizon Therapeutics plc Announces Availability of PROCYSBI® (Cysteamine Bitartrate) Delayed-Release Oral Granules in Packets in the United States
    PDF Version
    Displaying 1 - 10 of 508 results